Clinical Overview: Personalized bacteriophage therapy may be considered for select patients experiencing bacterial infections when standard treatment methods have proven ineffective, are unavailable, or deemed inappropriate. The new consensus guideline emphasizes the importance of culture-confirmed pathogen identification, phage susceptibility testing, multidisciplinary oversight, and continuous monitoring throughout the treatment process.
Bacteriophages, which are viruses specifically targeting bacteria, have re-emerged as a potential solution for challenging infections due to the increasing rates of antimicrobial resistance. Although phage therapy has been utilized in compassionate-use scenarios across the globe, the absence of standardized clinical and manufacturing directives has hindered its wider adoption. The newly established consensus guideline, supported by multiple international infectious disease organizations, aims to offer a practical framework for integrating personalized phage therapy into clinical practice.
Published in Nature Medicine, the guideline includes more than 60 recommendations addressing aspects such as patient selection, infrastructure, phage preparation, quality control, administration, and future research priorities. The authors characterize it as “the first detailed and consensus-based statement on personalized phage therapy” that “paves the way for the safe and standardized use of personalized phage therapy.”
Among the essential recommendations, clinicians are encouraged to consider personalized phage therapy for bacterial infections when conventional treatment options have failed or cannot be utilized. The document strongly advocates for culture-based pathogen identification, antimicrobial susceptibility testing, and the verification of bacterial susceptibility to selected phages as close to the start of treatment as feasible. In life-threatening scenarios, phage therapy may also be initiated even before susceptibility results are available if broad-spectrum phage cocktails can be accessed.
The guideline underscores the necessity of multidisciplinary decision-making that involves infectious disease specialists, microbiologists, pharmacists, and phage experts. For polymicrobial infections, all relevant pathogens should undergo phage susceptibility testing. Treatment plans ought to consider prior antibiotic usage, infection severity and site, implanted devices, comorbid conditions, and concurrent medications.
Given that phages are exceptionally targeted and customized, the guideline establishes standards for phage sourcing, production, storage, labeling, and quality control. The authors recommend systematic documentation of cases in national or international registries to enhance evidence generation and help fill significant knowledge gaps regarding efficacy, optimal dosing, and phage-antibiotic combinations.
Importantly, the document concludes that existing evidence indicates phage therapy is generally safe when appropriate quality standards are adhered to, without clear safety concerns identified thus far in children, immunocompromised patients, or during pregnancy, though data remains limited and decisions should be personalized.
Disclaimer: This content is intended for informational purposes only and should not be construed as medical advice. Always consult with a healthcare professional for medical guidance specific to your condition.
Join the doctors who get the most relevant medical news, curated by specialty, every week — no spam, unsubscribe anytime.
